Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q2 2018 call → NOWe need answer YES or NO based on transcript. Need identify if management describes company currently living through defined waiting period paying out of own pocket with cost currently landing, benefit not yet arrived, end specific near-dated event already working toward. Let's examine transcript. Key topics: Calcimimetics transition from Part D to Part B, moving pharmacy to clinics. Rice says: "Calcimimetics; they continue to evolve. As you remember, we're moving from Part D in David to Part B in Barry. Pharmacy to the clinics. We believe that we're probably two quarters in to two to four quarter process in order to get this sorted out with great clarity in detail. Let's keep in mind that this is a medical decision, it's an algorithm based on focusing to the highest outcomes for our patients and this is a titration, our step up situation where we start with low doses and move up overtime in a very safe and effective way as determined by our patients physicians." This sounds like a transition period. Mike Brosnan discusses Calcimimetics effect on revenue and cost per treatment. He says "we will see some volatility and the development of Calcimimetics over the year, which I why I guided revenue and cost per treatment in the US net of this effect. I indicated we expected the operating earnings effect of Calcimimetics on a net basis to be around $1 loss for the year. I'm continuing to indicate that as our expectation for 2018." So they are bearing cost (loss) due to transition, but benefit? The transition is from Part D to Part B, moving pharmacy to clinics. They are in process. Is this a defined waiting period? They say "two quarters in to two to four quarter process" to get sorted out. The end is specific? They expect to sort out in 2-4 quarters, so within about a year. They are paying now (loss) for something not yet earning? The Calcimimetics transition is causing lower revenue per treatment and cost per treatment, net loss $1 for year. But is it "paying now for something not yet earning"? The transition is a change in reimbursement channel, not necessarily investment. They are bearing cost due to implementation. Management describes it as a process, not apologizing. They are working toward it.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.